Vericel raises 2026 revenue guidance, launches $200 million buyback

Vericel Corporation reported second-quarter 2026 results on July 30, 2026, and raised its full-year revenue outlook while announcing new capital return plans. The company now expects total revenue of $330 to $340 million, up from prior guidance of $326 to $336 million, with MACI revenue guidance raised to $284 to $290 million and Burn Care revenue guidance raised to $46 to $50 million.¹ Vericel reaffirmed its full-year profitability targets of approximately 75% gross margin and approximately 27% adjusted EBITDA margin.¹

On the regulatory side, Vericel submitted a marketing authorization application for MACI to the U.K.'s MHRA during the quarter.¹

Commercial momentum continued across product lines. MACI revenue growth reached 20% or more for the fifth consecutive quarter, with a four-quarter trailing growth rate of 23%.¹ NexoBrid posted its highest quarterly revenue on record, growing 36% sequentially and 33% year over year, while Epicel revenue grew 21% in the quarter.¹ The company also reported double-digit growth in MACI biopsies and implants, setting quarterly records for biopsies, implants and the number of surgeons performing both procedures.¹

Financially, total revenue for the quarter rose to $77.5 million from $63.2 million a year earlier, an increase of 22%.¹ Net income was $2.2 million, and free cash flow was $14.3 million.¹ The company ended the quarter with approximately $227 million in cash and investments and no debt.¹

The board also authorized a new capital return program. Directors approved a $200 million share repurchase program.¹ CEO Nick Colangelo said the company's financial performance and balance sheet strength allow it to keep investing in long-term growth while opportunistically returning capital to shareholders through its first share repurchase program.¹